Insights From the Analysis of Clinicopathological and Prognostic Factors in Patients With Gallbladder Cancer

Di Wu†, Wenjian Jin†, Yue Zhang, Yong An, Xuemin Chen* and Weibo Chen*

Department of Hepatopancreatobiliary, Third Affiliated Hospital of Soochow University, Changzhou, China

**Aims:** To investigate the clinical efficacy and prognostic factors of primary gallbladder cancer (GBC) treated by radical surgery.

**Methods:** The clinical and pathological data of 168 patients with primary gallbladder cancer admitted and treated in the Third Affiliated Hospital of Soochow University from January 1st, 2010 to December 31st, 2018 were analyzed retrospectively. Kaplan Meier method was used to draw the survival curve and evaluate the survival rate. Chi-square test was used for univariate analysis and binary logistic regression was used for multivariate analysis.

**Results:** 94 cases showed symptoms of abdominal pain and abdominal distension. 7 cases showed symptoms of fatigue and weight loss. Jaundice occurred in 10 patients. Fever occurred in 6 patients. 51 patients had no symptoms at all. The median survival time of 168 patients was 35.0 (1.0 ~ 142.0) months. The overall 1-, 2- and 3-year cumulative survival rates were 69.6%, 55.4% and 48.8% respectively. The univariate analysis indicated that preoperative bilirubin, tumor size, tumor location, pathological type, degree of differentiation, liver invasion, nerve invasion, vascular invasion, surgical margin, filtration depth and N staging were significant factors influencing prognosis of patients with primary GBC (P<0.05). The results of multivariate analysis demonstrated that degree of differentiation, nerve invasion, filtration depth and N staging were independent risk factors for prognosis of patients with primary GBC (P<0.05).

**Conclusion:** Patients with risk factors of gallbladder cancer should be more active in early cholecystectomy to avoid the malignant transformation of benign diseases. Degree of differentiation, nerve invasion, filtration depth and N staging were important factors for poor prognosis of patients with primary GBC. For T4 staging patients, preoperative evaluation should be more comprehensive, and patients and surgeons should be more prudent in adopting appropriate clinical treatment. The primary purpose should be prolonging the survival time and improving the quality of life.

**Keywords:** gallbladder cancer (GBC), preventive surgery, advanced gallbladder cancer, comprehensive therapy, prognostic factors
INTRODUCTION

Primary GBC is one of the most common malignant tumors in the biliary system. GBC is highly malignant, the early diagnosis of which is difficult, and the prognosis is very poor. Radical resection is still the most effective treatment to improve the prognosis of GBC patients (1). The 5-year survival rate of gallbladder cancer is only about 10% ~ 30% (2). In recent years, with the deepening understanding of the disease, its treatment mode has been transformed into multidisciplinary comprehensive treatment based on surgery. The scope of liver resection and lymph node dissection has been expanded. Adjuvant treatments such as postoperative chemotherapy, preoperative neoadjuvant chemotherapy and targeted drug therapy have been gradually carried out (3). Even so, the long-term survival rate is still poor. Therefore, this study retrospectively analyzed the clinical and pathological data of 168 patients with GBC treated in the Third Affiliated Hospital of Soochow University from January 1st, 2010 to December 31st, 2018 to explore the long-term clinical efficacy of radical resection and independent risk factors affecting the prognosis of patients with GBC.

MATERIALS AND METHODS

Study Design and Data Collection

This study is a retrospective comparative study performed in a single center. Data were collected retrospectively.

Inclusion Criteria and Exclusion Criteria

The inclusion criteria were as follows: 1. Postoperative routine pathology confirmed the diagnosis of GBC, 2. No distant metastasis occurred, 3. Patients all underwent radical surgery, 4. No other malignant tumors existed.

The exclusion criteria were as follows: 1. Patients underwent palliative surgery or patients underwent preoperative neoadjuvant therapy, 2. Clinical data of the patients were incomplete, or the patients were lost during follow-up.

Preoperative Examination

Laboratory tests include blood routine test, hepatic and renal functions, tumor markers and so on. Electrocardiogram and pulmonary function were routinely performed to exclude the surgical contraindications. B ultrasound, CT and (or) MRI were performed to obtain a correct diagnosis. PET-CT was used when previous examination could not provide a clear diagnose or distant metastasis could not be excluded.

Surgical Procedure

Preoperative staging and operation plan was made according to preoperative examination. The stages were further defined by surgical exploration and rapid pathology, and the corresponding radical surgery was carried out based on different stages. Patients under stage tis and T1a underwent laparoscopic or open cholecystectomy while patients under T1b–T3 needed cholecystectomy + lymph node dissection + hepatectomy according to different conditions. (For T1b and T2 staging patients, wedge resection of liver was performed, and for T3 staging patients, resection of segment IVB+V of liver was performed). However, for patients under stage T4, combined organ resections such as right colectomy, subtotal gastrectomy and pancreatoduodenectomy were needed. Extent of lymph-node dissection included dissection of group 8, 12 and 13a lymph nodes.

Pathological Diagnostic Criteria

Tumor staging was evaluated based on the 8th edition of AJCC Cancer staging system.

Clinical and Pathological Materials

The clinical manifestations, preoperative imaging and laboratory examination results, surgical methods, pathological data, and survival time were analyzed. Gender, age, preoperative total bilirubin, tumor size, tumor location, pathological type, degree of differentiation, liver invasion, nerve invasion, vascular invasion, surgical margin, filtration depth, N stage and postoperative adjuvant chemotherapy were included in univariate and multivariate analysis.

Follow-Up Model

All patients were followed up by telephone or by out-patient. The follow up period ended on December 31, 2021, or death.

Statistical Analysis

Normal distributions of numerical variable data were verified with Shapiro Wilk test. Numerical variable data were presented as mean and standard deviation (SD). Categorical variable data were presented as number and percentages (4). Kaplan Meier method was used to draw the survival curve and calculate the survival rate. χ² test and Fisher’s exact test was used for univariate survival analysis, and Cox regression model was used for multivariate analysis. SPSS software (SPSS Statistics 17.0) was used for data analysis and a statistically significant difference was considered for a value of P<0.05.

RESULTS

General Information of Patients

A total of 168 patients with primary gallbladder cancer were included, including 52 males and 116 females, with a male to female ratio of 0.45:1. The age ranged from 29 to 90 years old, with an average of (65.14 ± 11.78) years old.

Clinical Manifestation

94 cases showed symptoms of abdominal pain and abdominal distension. 7 cases showed symptoms of fatigue and weight loss. Jaundice occurred in 10 patients. Fever occurred in 6 patients. 51 patients had no symptoms at all.

Abbreviations: GBC, gallbladder cancer; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography computed tomography; AJCC, American joint committee on cancer; SD, standard deviation; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 199; CA125, carbohydrate antigen 125; HPD, hepatopancreaticoduodenectomy.
Diagnostic Imaging and Laboratory Data
The diagnostic accuracy of abdominal B-ultrasound, CT and MRI were 48.34% (73/151), 73.60% (92/125), and 59.67% (37/62), while the diagnostic accuracy of CEA, CA199, CA125 were 26.67% (36/135), 45.45% (60/132), and 20.77% (27/130).

Surgical Procedure
All the 168 patients underwent radical resection of GBC. Among them, 41 patients underwent laparoscopic surgery, including 13 cases of laparoscopic cholecystectomy and 28 cases of laparoscopic radical resection. The rest 127 patients underwent open surgery, among which, 117 patients underwent wedge resection or IVB+V segment resection of liver. The rest included 4 cases of hepatopancreaticoduodenectomy (HPD), 3 cases of right hepatectomy and 3 cases of combined subtotal gastrectomy and right colectomy.

Postoperative Complications
Postoperative complications occurred in ten patients. Postoperative bleeding was observed in three patients, but none of them needed second operation. All they needed were prolonged drain time and intravenous infusion of hemostatic drugs. Two patients developed pleural effusion and were relieved after pleural puncture and drainage. Two patients developed bile leakage and three patients developed pancreatic fistula and they were improved by prolonged drain time.

Pathological Results
153 patients were diagnosed with adenocarcinoma. Among them, there were 3 cases of papillary adenocarcinoma, 3 cases of tubular adenocarcinoma, 1 case of fungating adenocarcinoma. Non adenocarcinoma patients include 11 cases of adeno-squamous carcinoma, 3 cases of squamous cell carcinoma and 1 case of sarcomatoid carcinoma. As with the degree of differentiation, 80 patients were highly differentiated, 45 patients were moderately differentiated, and 43 patients were poorly differentiated. In 86 cases, the tumors were located at the bottom of the gallbladder, 62 at the body of the gallbladder and 20 at the neck of the gallbladder. Liver invasion occurred in 50 patients. Nerve invasion occurred in 28 patients. Vascular invasion occurred in 18 patients. The number of patients with tumor stage 0, I, II, III, IV were 9, 26, 57, 62 and 14 respectively.

Follow-Up Data
The median survival time of this group was 35.0 (1.0 ~ 142.0) months. The cumulative survival rates of all patients at 1, 2 and 3 years were 69.6%, 55.4% and 48.8% respectively (Figures 1, 2).

Univariate Analysis of Prognosis
Univariate analysis showed that preoperative total bilirubin, tumor size, tumor location, pathological type, degree of differentiation, liver invasion, nerve invasion, vascular invasion, surgical margin, filtration depth and N stage were the risk factors affecting the prognosis of gallbladder cancer (P < 0.05). Gender, age, and postoperative adjuvant chemotherapy were not important factors affecting the prognosis (Table 1).

Multivariate Analysis of Prognostic Factors
Multivariate analysis demonstrated that degree of differentiation, nerve invasion, filtration depth and N staging were important factors for poor prognosis of patients with primary GBC (P < 0.05) (Table 2).

DISCUSSION
Gallbladder cancer is a highly malignant tumor of the digestive system. It has no special manifestations at an early stage. When non-specific symptoms such as upper abdominal pain, abdominal distension, and even jaundice occurred, it often indicated tumors in progressive stage. The incidence rate of gallbladder cancer in China accounts for 0.4%~3.8% of biliary tract diseases, ranking sixth in digestive tract cancer, and 5 years survival rate of gallbladder cancer is only 5% (5). Risk factors for

![FIGURE 1 | Overall survival curve of 168 patients with gallbladder cancer treated by radical surgery.](#)
gallbladder cancer consist of cholecystolithiasis, polypoid lesions of the gallbladder and chronic cholecystitis. In our study, 51 patients had no symptoms at all. They were diagnosed by B-ultrasound, CT, or MRI by accident. Most of the 51 patients had risk factors for gallbladder cancer. None of them had undergone preventive cholecystectomy before malignant transformation.

It is reported that about 85% of patients with gallbladder cancer are complicated with cholecystolithiasis (5). The risk of gallbladder cancer in patients with cholecystolithiasis is 13.7 times higher than that in people without cholecystolithiasis. The diameter and number of gallstones are positively correlated with the occurrence of gallbladder cancer. Cholesterol and mixed cholesterol gallstones have an even higher risk (6).

Cholecystectomy is recommended for symptomatic cholecystolithiasis (7). For asymptomatic cholecystolithiasis, whether surgical treatment should be performed is still controversial in China. As far as I am concerned, since gallstone is a risk factor for gallbladder cancer, gallstone is one of the surgical indications. But right now, for Chinese people, it is unacceptable to resect a “normal” organ without any symptoms. Patients with asymptomatic cholecystolithiasis who are not willing to undergo surgery for the time being should be closely followed up. Cholecystectomy should be carried out in time in case of clinical symptoms occurred, or cholecystolithiasis related complications (acute pancreatitis, common bile duct stones or cholangitis, etc.) occurred or when there were risk factors for gallbladder cancer (7, 8).

Multivariate analysis demonstrated that the filtration depth is one of the risk factors affecting the prognosis of gallbladder cancer, which is consistent with the latest research results (9–11). In our study, the median survival time of T4 patients after extended radical resection was 3 months, which was much lower than that of other stages. It is still controversial whether T4 stage gallbladder cancer without distant metastasis can be treated with extended radical resection combined with multiorgan resection and vascular reconstruction. A retrospective clinical study by Chen et al. showed that the median survival time of stage T4 gallbladder cancer without surgery was only 2.3 months, while the survival time could be significantly prolonged by radical surgery (12). D’Souza insisted that although HPD was associated with perioperative mortality and morbidity, it can still offer a survival benefit in patients with GBC (13). Kuipers had reached the similar conclusion (14). However, some experts took a more cautious attitude. Considering the high morbidity rate and the advanced stage of the disease, Sakamoto hold the idea that the indication for HPD in advanced stage gallbladder cancer should be considered carefully (15). In our study, 4 patients underwent HPD, and three of them had developed pancreatic fistula. In our opinion, extended radical resection is a double-edged sword. Extended radical resection does provide a survival benefit. Perioperative mortality and morbidity can’t be neglected. HPD carries high morbidity and mortality rates. The reported incidence of mortality after HPD has been reported to be as high as 33% (16–19). Hepatic failure and pancreatic fistula account for most of the perioperative mortality. However, 3 patients undergoing right hepatectomy and 3 patients undergoing combined subtotal gastrectomy and right colectomy, no postoperative complications occurred. Few studies have reported the perioperative mortality and morbidity of extended radical resection other than HPD. Therefore, for extended radical resection other than HPD, adequate preoperative evaluation including general condition, liver function, nutritional status should be accomplished. As with HPD, treatment decisions should be more conservative. After all, the primary purpose of medical treatment should be prolonging the survival time and improving the quality of life. We still have many options dealing with GBC besides surgery. In recent years, many clinical studies have explored the adjuvant chemotherapy, which has changed the treatment status of gallbladder cancer (20–24). At the same time, molecular targeted therapy and immunotherapy of gallbladder cancer have also achieved encouraging results. In the future, comprehensive therapy is expected to bring greater survival benefits to patients with gallbladder cancer.

Still, our work has its limitations. First of all, it was performed in a single center. The results may be influenced by subjective factors such as surgical skills. Secondly, this study was a retrospective study and prospective randomized controlled trial.
is more convincing. In the near future, maybe we will participate in a multicenter randomized controlled trial.

In conclusion, patients with risk factors of gallbladder cancer should be more active in early cholecystectomy to avoid the malignant transformation of benign diseases. For T4 staging patients, preoperative evaluation should be more comprehensive, and patients and surgeons should be more prudent in adopting appropriate clinical treatment. The
primary purpose should be prolonging the survival time and improving the quality of life.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Third Affiliated Hospital of Soochow University. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Wistuba II, Gazdar AF. Gallbladder Cancer: Lessons From a Rare Tumour. *Nat Rev Cancer* (2004) 4(9):695–706. doi: 10.1038/nrc1429
2. Miranda-Filho A, Pineros M, Ferreccio C, Adsay V, Soerjomataram I, Bray F, et al. Gallbladder and Extrapancreatic Bile Duct Cancers in the Americas: Incidence and Mortality Patterns and Trends. *Int J Cancer* (2020) 147 (4):978–89. doi: 10.1002/ijc.32863
3. Lindner P, Holmberg E, Hafstrom L. Gallbladder Cancer - No Improvement in Survival Over Time in a Swedish Population. *Acta Oncol* (2018) 57 (11):1482–9. doi: 10.1080/0284186X.2018.1478124
4. Tan X, Wang G, Tang Y, Bai J, Tao K, Ye L. Minilaparoscopic Versus Single Incision Cholecystectomy for the Treatment of Cholecystolithiasis: A Meta-Analysis and Systematic Review. *BMC Surg* (2017) 17(1):91. doi: 10.1186/s12893-017-0287-x
5. Hundral R, Shaffer EA. Gallbladder Cancer: Epidemiology and Outcome. *Clin Epidemiol* (2014) 6:99–109. doi: 10.2147/CLEP.S37357
6. Roa I, Ibacache G, Roa J, Araya J, de Aretxabala X, Munoz S. Gallstones and Gallbladder Cancer-Volume and Weight of Gallstones are Associated With Gallbladder Cancer: A Case-Control Study. *J Surg Oncol* (2006) 93(8):624–8. doi: 10.1002/jso.20528
7. Gutt C, Schlafer S, Lammert F. The Treatment of Gallstone Disease. *Dtsch Arztebl Int* (2020) 117(14–15):188–95. doi: 10.3238/arztebl.2020.0148
8. Tazuma S, Unno M, Igarashi Y, Inui K, Uchiyama K, Kai M, et al. Evidence-Based Clinical Practice Guidelines for Cholelithiasis 2016. *J Gastroenterol* (2017) 52(3):276–300. doi: 10.1007/s00535-016-1289-7
9. Yang XW, Chen JY, Wen ZJ, Li YL, Wang FY, Li L, et al. Effect of Preoperative Jaundice on Long-Term Prognosis of Gallbladder Carcinoma With Radical Resection. *World J Surg Oncol* (2020) 18(1):239. doi: 10.1186/s12957-020-02015-2
10. Gani F, Buettner S, Margonis GA, Euthen CG, Poultsides G, Tran T, et al. Assessing the Impact of Common Bile Duct Resection in the Surgical Management of Gallbladder Cancer. *J Surg Oncol* (2016) 114(2):176–80. doi: 10.1002/jso.24283
11. Higuchi R, Yazawa T, Uemura S, Matsunaga Y, Ota T, Araida T, et al. Examination of Prognostic Factors Affecting Long-Term Survival of Patients With Stage 3/4 Gallbladder Cancer Without Distant Metastasis. *Cancers (Basel)* (2020) 12(8):2073. doi: 10.3390/cancers12082073
12. Chen C, Geng Z, Shen H, Song H, Zhao Y, Zhang G, et al. Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage. *PloS One* (2016) 11(11):e0166361. doi: 10.1371/journal.pone.0166361
13. D’Souza MA, Valdimarsson VT, Campagnaro T, Cauchi F, Chatzizacharias NA, D’Hondt M, et al. Hepatopancreatoduodenectomy – a Controversial Treatment for Bile Duct and Gallbladder Cancer From a European Perspective. *HPB (Oxford)* (2020) 22(9):1339–48. doi: 10.1016/j.hpb.2019.12.008
14. Kuipers H, de Savornin Lohman EAJ, van Dooren M, Braat AE, Daams F, van Dam R, et al. Extended Resections for Advanced Gallbladder Cancer: Results From a Nationwide Cohort Study. *Ann Surg Oncol* (2021) 28(2):835–43. doi: 10.1245/s10434-020-08858-z
15. Sakamoto Y, Nara S, Kishi Y, Etsuki M, Shimada K, Nakano K, et al. Is Extended Hemigastrectomy Plus Pancreaticoduodenectomy Justified for Advanced Bile Duct Cancer and Gallbladder Cancer? *Surgery* (2013) 153 (6):794–800. doi: 10.1016/j.surg.2012.11.024
16. Nimura Y, Hayakawa N, Kuniyama J, Maeda S, Kondo S, Yasui A, et al. Hepatopancreatoduodenectomy for Advanced Carcinoma of the Biliary Tract. *Hepatogastroenterology* (1991) 38(2):170–5. doi: 10.11136/gut.32.4.458-a
17. Tsukada K, Yoshida K, Aono T, Koyama S, Shirai Y, Uchida K, et al. Major Hepatocarcinoma and Pancreaticoduodenectomy for Advanced Carcinoma of the Biliary Tract. *Br J Surg* (1994) 81(1):108–10. doi: 10.1002/bjs.1800810139
18. Nakamura S, Nishiyama R, Yokoi Y, Serizawa A, Nishiwaki Y, Komho H, et al. Hepatopancreatoduodenectomy for Advanced Gallbladder Carcinoma. *Arch Surg* (1994) 129(6):625–9. doi: 10.1001/archsurg.1994.01420300069010
19. Miyagawa S, Makuuchi M, Kawasaki S, Hayashi K, Harada H, Kitamura H, et al. Outcome of Major Hepatocarcinoma With Pancreatoduodenectomy for Advanced Biliary Malignancies. *World J Surg* (1996) 20(1):77–80. doi: 10.1002/sde.2689000104
20. Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, et al. Randomized Phase III Study of Gemcitabine Plus s-1 Versus Gemcitabine Plus Cisplatin in Advanced Biliary Tract Cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). *Ip j Clin Oncol* (2016) 46(4):385–8. doi: 10.1093/jco/ovy213
21. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Cetuximab in Extrapancreatic Cholangiocarcinoma and Gallbladder Carcinoma. *J Clin Oncol* (2015) 33(24):2617–22. doi: 10.1200/JCO.2014.60.2219
22. Fukutomi A, Furuse J, Okusaka T, Miyazaki M, Taketsuna M, Koshiji M, et al. Effect of Biliary Drainage on Chemotherapy in Patients With Biliary Tract Cancer: An Exploratory Analysis of the BT22 Study. *HPB (Oxford)* (2012) 14 (4):221–7. doi: 10.1111/j.1477-2578.2011.01341.x
23. Edeline J, Benabdelghani M, Bertaut A, Watelot J, Hamel P, Joly JP, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. *J Clin Oncol* (2013) 31(37):6568–76. doi: 10.1200/JCO.2013.54.0050
24. Primrose JN, Fox RP, Palmis HZ, Prasad R, Mirza D, et al. Capecitabine Compared With Observation in Resected Biliary Tract Cancer
(BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study. *Lancet Oncol* (2019) 20(5):663–73. doi: 10.1016/S1470-2045(18)30915-X

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Jin, Zhang, An, Chen and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.